Stock Events

Stock Events

Search...

Cartesian Therapeutics

€0.45

3

-€13.47-96.8% Thursday 14:00

Statistics

Day High

0.45

Day Low

0.45

52W High

-

52W Low

-

Volume

0

Avg. Volume

-

Mkt Cap

2.46M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

1NovExpected

Q1 2022

Q2 2022

Q3 2022

Q4 2022

Q1 2023

Q2 2023

Q3 2023

-0.14

-0.02

0.11

0.23

Expected EPS

-0.1097

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1S7.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Adaptimmune Therapeutics

Adaptimmune Therapeutics focuses on T-cell therapy for cancer, similar to Cartesian's approach in cell-based immunotherapies.

Allogene Therapeutics

Allogene Therapeutics is involved in the development of allogeneic CAR-T therapies, competing in the same space as Cartesian's cell therapy products.

CRISPR Therapeutics

CRISPR Therapeutics is engaged in gene editing and cell therapy, including CAR-T therapies, which puts them in direct competition with Cartesian.

bluebird bio focuses on gene therapies and cell therapies for severe genetic diseases and cancer, overlapping with Cartesian's therapeutic areas.

Novartis is a large pharmaceutical company with Kymriah, a CAR-T cell therapy for cancer, making it a competitor in Cartesian's market.

Gilead Sciences

Gilead Sciences, owning Kite Pharma, competes in the CAR-T and cell therapy space, directly challenging Cartesian's therapeutic approaches.

Pfizer is involved in various therapeutic areas, including investments in gene therapy and cell therapy, potentially competing with Cartesian's technologies.

About

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Show more...

CEO

Dr. Carsten Brunn Ph.D.

Employees

37

Country

US

ISIN

US8162121045

WKN

000A2AML0

Listings